Breast cancer is a heterogeneous disease, and within the HER-2 positive subtype this is highly exemplified by the presence of substantial phenotypical and clinical heterogeneity, mostly related to hormonal receptor (HR) expression. It is well known how HER-2 positivity is commonly associated with ...
Triple-positive breast cancerTumor-infiltrating lymphocytesTumor microenvironmentNeoadjuvant chemotherapyBreast cancer remains a leading cause of cancer-related mortality among women, with triple-positive breast cancer (TPBC) being a particularly aggressive subtype. GATA binding protein 3 (GATA3) plays a ...
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer[J]. BMC Med, 2015, 13: 177. doi: 10.1186/s12916-015-0416-2 [35] Marotta LL, Almendro V, Marusyk A, et al. The JAK2/STAT3 signaling pathway is ...
The first FDA accelerated approval of an ICI for the treatment of breast cancer came in March 2019 when the anti-PD-L1 antibody atezolizumab was approved in combination with nab-paclitaxel as a first-line treatment for patients with PD-L1-positive, metastatic TNBC based on the IMpassion130 tria...
HER2-Positive Breast Cancer In about 20% of breast cancers, the cells make too much of a protein known as HER2. These cancers tend to be aggressive and fast-growing. For women with HER2-positive breast cancers, the targeted drugtrastuzumab(Herceptin) has been shown to dramatically reduce the...
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the su
(SORT1). TH1902 is internalized in cancer cells through SORT1 [257]. TH1902 exerts a superior anticancer activity than unconjugated docetaxel in human SORT1-positive ovarian and triple-negative breast cancer xenograft models [257,258,259]. TH1902 is currently being evaluated in a phase I ...
Triple Negative Breast Cancer research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in triple negative breast cancer clinical trials today.
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer[J]. BMC Med, 2015, 13: 177. doi: 10.1186/s12916-015-0416-2 [35] Marotta LL, Almendro V, Marusyk A, et al. The JAK2/STAT3 signaling pathway is ...
BM preferentially develop in metastatic patients with HER2 -positive disease and triple-negative breast cancers (TNBC), which lack estrogen receptor (ER), progesterone receptor (PR), and HER2 alterations [3,4]. Development of BM predicts poorest survival in TNBC patients and results in death withi...